Stay updated on Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.

Latest updates to the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe webpage has added several new dates and a document related to informed consent from M.D. Anderson Cancer Center, while removing outdated dates and a notice about service performance issues.SummaryDifference4%
- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check40 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check54 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check62 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in its functionality.SummaryDifference0.3%
- Check90 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
Stay in the know with updates to Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.